Written by the Core Power Peptides Research Team — biochemists and laboratory specialists compiling and verifying peptide research data. Learn about our quality standards →
The choice between CJC-1295 with and without DAC comes down to a single research question: does the protocol need physiological pulsatility, or sustained elevation? Without DAC the compound clears in 30–60 minutes and GH returns to baseline between doses — mimicking natural secretion rhythms in a way the week-long DAC-modified version cannot.
Modified GRF 1-29: Short Half-Life by Design
CJC-1295 Without DAC (Modified GRF 1-29) is a synthetic 30-amino acid growth hormone releasing hormone analog that stimulates pituitary GH secretion in a short-acting pulsatile pattern. Its shorter half-life (~30–60 minutes vs. 6–8 days for the DAC-modified version) makes it particularly suitable for research protocols that require mimicking the physiological pulsatility of endogenous GH secretion rather than continuous sustained elevation.
Combined with ipamorelin, CJC-1295 Without DAC represents the most widely used GH secretagogue dual-pathway stack in preclinical research — with GHRHR activation (CJC-1295) and GHS-R1a activation (ipamorelin) producing synergistic GH responses 5–10× above baseline in rodent models.
Mechanism of Action
- GHRHR Agonism: Directly activates growth hormone-releasing hormone receptors on pituitary somatotrophs
- cAMP Cascade: GHRHR activation increases intracellular cAMP and PKA, triggering GH synthesis and pulse release
- Pulsatility Preservation: Short half-life (without DAC) allows GH to return to baseline between doses, mimicking natural secretion rhythms
- GHRH + GHS-R Synergy: CJC-1295 + ipamorelin co-activation produces supra-additive GH release via simultaneous GHRH and ghrelin pathway stimulation
Research Data
- Dose-dependent GH elevation: 1–100 µg/kg produces 2–10× baseline GH in rodents
- Peak GH response 15–30 min post-administration, return to baseline by 2–3 hours
- Combination with ipamorelin: GH response 5–10× greater than either compound alone
- No tachyphylaxis in twice-daily dosing protocols over 4-week periods
- IGF-1 normalization in GH-deficient rodent models with daily dosing
CJC-1295 With vs. Without DAC — Quick Reference
| Parameter |
Without DAC |
With DAC |
| Half-life |
30–60 min |
6–8 days |
| Dosing frequency |
1–3× daily |
1× weekly |
| GH pattern |
Pulsatile (physiological) |
Continuous elevation |
| Research use |
Acute/combination studies |
Chronic protocol studies |
CJC-1295 Research Products
HPLC Verified
CJC-1295 Without DAC 5mg
Purity: 99%+ HPLC
Half-Life: 30–60 min
Format: Lyophilized Powder
$45
Buy Now
HPLC Verified
CJC-1295 With DAC 10mg
Purity: 99%+ HPLC
Half-Life: 6–8 days
Format: Lyophilized Powder
$65
Buy Now
HPLC Verified
Ipamorelin / CJC-1295 Blend 10mg
Purity: 99%+ HPLC
Synergistic: Dual pathway
Format: Lyophilized Powder
$120
Buy Now
Frequently Asked Questions
When is the non-DAC form the better research choice?
Acute studies and combination protocols. The 30–60 minute half-life allows GH to return to baseline between doses, which is what makes it suitable for modeling physiological pulsatility. Chronic exposure protocols requiring sustained baseline elevation generally use the DAC-modified version instead — the full DAC comparison guide covers both side by side.
Is Modified GRF 1-29 the same thing as CJC-1295 without DAC?
Yes — the terms are used interchangeably for the same 30-amino acid GHRH analog.
Why combine it with ipamorelin?
The two engage separate receptors: CJC-1295 activates GHRHR, while ipamorelin activates GHS-R1a. Co-activation produces supra-additive GH release — 5–10× above baseline in rodent models — compared with either compound used alone.
Provided as laboratory reference material. CJC-1295 from Core Power Peptides is for in vitro and research use exclusively; it is not intended for human consumption and carries no medical claims.
